Claims for Patent: 10,261,083

Summary for Patent: 10,261,083

Title:	Compositions and methods for detecting protease activity in biological systems
Abstract:	The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
Inventor(s):	Vasiljeva; Olga (Cupertino, CA), Menendez; Elizabeth-Edna Mary (San Mateo, CA)
Assignee:	CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:	14/147,324
Patent Claims:	1. A method of detecting presence or absence of a co-localized cleaving agent and a target in a tissue sample bound to a support matrix, the method comprising: (a) contacting the tissue sample bound to a support matrix with an uncleaved activatable antibody, wherein the uncleaved activatable antibody comprises an antibody or an antigen binding fragment thereof (AB) that specifically binds to a target, wherein the AB is (i) an antibody selected from the group of antibodies consisting of: bevacizumab, ranibizumab, cetuximab, panitumumab, infliximab, adalimumab, natalizumab, basiliximab, eculizumab, efalizumab, tositumomab, ibritumomab tiuxetan, rituximab, ocerlizumab, ofatumumab, obinutuzumab, daclizumab, brentuximab vedotin, gemtuzumab ozogamicin, alemtuzumab, abiciximab, omalizumab, trastuzumab, emtansine, palivizumab, ipilimumab, tremelimumab, Hu5c8, pertuzumab, ertumaxomab, abatacept, tanezumab, bavituximab, zalutumumab, mapatumumab, matuzumab, nimotuzumab, ICR62, mAb 528, CH806, MDX-447, edrecolomab, RAV12, huJ591, etanercept, alefacept, ankinra, GC1008, adecatumumab, figitumumab, tocilizumab, ustekinumab, and denosumab, or an antigen binding fragment of said antibody selected from the group of antibodies, or (ii) an antibody that binds to a target selected from the group consisting of: 1-92-LFA-3, Anti-Lewis-Y, Apelin J receptor, APRIL, BAFF, C5 complement, C-242, CD2, CD3, CD9, CD11a, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD40, CD40L, CD41, CD44, CD47, CD52, CD56, CD64, CD70, CD80, CD86, CD95, CD117, CD132, (IL-2RG), CD133, CD137, CD138, CD172A, CEACAMS (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLL4, DPP-4, EGFR, Endothelin B receptor (ETBR), EpCAM, EPHA2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, Folate receptor, G-CSF, G-CSFR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP llb/IIIa receptors, Gp130, GPIIB/IIIA, GPNMB, HER2/neu, HGF, hGH, Hyaluronidase, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27/IL27R (wsx1), IL29, IL-31R, IL31/IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, LIF-R, MRP4, MUC1, Mucin-16, Na/K ATPase, Neutrophil elastase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, P1GF, PSCA, PSMA, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, TGFbeta, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TNFalpha, TNFR, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, WISP-1, WISP-2, WISP-3, Alpha-4 integrin, Alpha-V integrin, and alpha4betal integrin, or an antigen binding fragment of said antibody that binds to a target selected from the group of targets, a masking moiety (MM) coupled to the AB that inhibits the binding of the AB of the activatable antibody in an uncleaved state to the target, wherein the MM of the activatable antibody in an uncleaved state interferes with specific binding of the AB to the target, and a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a cleaving agent, wherein the cleaving agent is a protease, whereby cleavage of the uncleaved activatable antibody in the CM results in an activated activatable antibody, and wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM, (b) washing the tissue sample bound to the support matrix, and (c) measuring in situ the presence or absence of a detectable level of activated activatable antibody in the tissue sample, wherein presence of a detectable level of activated activatable antibody in the tissue sample indicates presence of a detectable level of co-localized cleaving agent and target in the tissue sample, and wherein absence of a detectable level of activated activatable antibody in the tissue sample indicates absence of a detectable level of co-localized cleaving agent and target in the tissue sample, whereby the cleaving agent, the target, or both the cleaving agent and the target, are absent or not present or not co-localized at a detectable level in the tissue sample, wherein the activated activatable antibody comprises a detectable label or wherein measuring in situ the presence or absence of a detectable level of activatable antibody in the tissue sample is accomplished using a secondary reagent that specifically binds to the activatable antibody, wherein the secondary reagent comprises a detectable label. 2. The method of claim 1, wherein the detectable label comprises an imaging agent, a contrasting agent, an enzyme, a fluorescent label, a chromophore, a dye, a radioisotope, one or more metal ions, or a ligand-based label. 3. The method of claim 1, wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, a scFv, and a scAb. 4. The method of claim 1, wherein the MM has an equilibrium dissociation constant for binding to the AB that is greater than the equilibrium dissociation constant of the AB to the target. 5. The method of claim 1, wherein the MM does not interfere or compete with the AB of the activatable antibody in a cleaved state for binding to the target. 6. The method of claim 1, wherein the MM is a polypeptide of no more than 40 amino acids in length. 7. The method of claim 1, wherein the MM polypeptide sequence is different from that of the target and wherein the MM polypeptide sequence is no more than 50% identical to any natural binding partner of the AB. 8. The method of claim 1, wherein the MM does not comprise more than 25% amino acid sequence identity to the target. 9. The method of claim 1, wherein the MM does not comprise more than 10% amino acid sequence identity to the target. 10. The method of claim 1, wherein the CM is a polypeptide of up to 15 amino acids in length. 11. The method of claim 1, wherein the activatable antibody comprises a linking peptide between the MM and the CM. 12. The method of claim 1, wherein the activatable antibody comprises a linking peptide between the CM and the AB. 13. The method of claim 1, wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2), and wherein the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-LP1 -CM-LP2-AB or AB-LP2-CM-LP1-MM. 14. The method of claim 13, wherein the two linking peptides need not be identical to each other. 15. The method of claim 13, wherein at least one of LP1 or LP2 comprises an amino acid sequence selected from the group consisting of (GS)n, (GGS)n, (GSGGS)n (SEQ ID NO: 33) and (GGGS)n (SEQ ID NO: 34), where n is an integer of at least one. 16. The method of claim 13, wherein at least one of LP1 or LP2 comprises an amino acid sequence selected from the group consisting of GGSG (SEQ ID NO: 35), GGSGG (SEQ ID NO: 36), GSGSG (SEQ ID NO: 37), GSGGG (SEQ ID NO: 38), GGGSG (SEQ ID NO: 39), and GSSSG (SEQ ID NO: 40). 17. The method of claim 1, wherein the activatable antibody in an uncleaved state comprises a spacer, wherein the spacer is joined directly to the MM and has the structural arrangement from N-terminus to C-terminus of spacer-MM-CM-AB. 18. The method of claim 1, wherein the support matrix is a slide. 19. The method of claim 1, wherein the AB is an antibody selected from the group of antibodies consisting of: bevacizumab, ranibizumab, cetuximab, panitumumab, infliximab, adalimumab, natalizumab, basiliximab, eculizumab, efalizumab, tositumomab, ibritumomab tiuxetan, rituximab, ocerlizumab, ofatumumab, obinutuzumab, daclizumab, brentuximab vedotin, gemtuzumab ozogamicin, alemtuzumab, abiciximab, omalizumab, trastuzumab, emtansine, palivizumab, ipilimumab, tremelimumab, Hu5c8, pertuzumab, ertumaxomab, abatacept, tanezumab, bavituximab, zalutumumab, mapatumumab, matuzumab, nimotuzumab, ICR62, mAb 528, CH806, MDX-447, edrecolomab, RAV12, huJ591 , etanercept, alefacept, ankinra, GC1008, adecatumumab, figitumumab, tocilizumab, ustekinumab, and denosumab, or an antigen binding fragment of said antibody selected from the group of antibodies. 20. The method claim 1, wherein the AB is an antibody that binds to a target selected from the group consisting of: 1-92-LFA-3, Anti-Lewis-Y, Apelin J receptor, APRIL, BAFF, C5 complement, C-242, CD2, CD3, CD9, CD11a, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD40, CD40L, CD41, CD44, CD47, CD52, CD56, CD64, CD70, CD80, CD86, CD95, CD117, CD132, (IL-2RG), CD133, CD137, CD138, CD172A, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLL4, DPP-4, EGFR, Endothelin B receptor (ETBR), EpCAM, EPHA2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, Folate receptor, G-CSF, G-CSFR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP IIb/IIIa receptors, Gp130, GPIIB/IIIA, GPNMB, HER2/neu, HGF, hGH, Hyaluronidase, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27/IL27R (wsxl), IL29, IL-31R, IL31/IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, LIF-R, MRP4, MUC1, Mucin-16, Na/K ATPase, Neutrophil elastase, NGF, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, P1GF, PSCA, PSMA, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, TGFbeta, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TNFalpha, TNFR, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, WISP-1, WISP-2, WISP-3, Alpha-4 integrin, Alpha-V integrin, and alpha4betal integrin, or an antigen binding fragment of said antibody that binds to a target selected from the group of targets.

Details for Patent 10,261,083

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2033-01-04
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2033-01-04
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2033-01-04
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2033-01-04
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-01-04